Top Page
Imugene
(Sydney:IMU)
Imugene (IMU) vs. iShares MSCI Australia ETF (EWA)
Imugene Business Overview & Revenue Model
Imugene Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.40M | 4.40M | 4.97M | 11.78M | 12.97M | 7.23M |
| Gross Profit | 4.40M | 4.40M | 4.97M | 9.57M | 10.56M | 5.27M |
| EBITDA | -67.42M | -67.42M | -147.98M | -47.42M | -48.06M | -23.72M |
| Net Income | -69.02M | -69.02M | -149.68M | -37.91M | -37.87M | -18.45M |
Balance Sheet | ||||||
| Total Assets | 83.59M | 83.59M | 151.40M | 197.06M | 147.61M | 71.81M |
| Cash, Cash Equivalents and Short-Term Investments | 21.94M | 21.94M | 94.54M | 153.15M | 99.89M | 29.49M |
| Total Debt | 10.65M | 10.65M | 2.19M | 553.47K | 673.43K | 271.03K |
| Total Liabilities | 38.56M | 38.56M | 33.14M | 7.44M | 8.90M | 6.79M |
| Stockholders Equity | 45.03M | 45.03M | 118.25M | 189.63M | 138.70M | 65.02M |
Cash Flow | ||||||
| Free Cash Flow | -83.12M | -90.03M | -108.80M | -29.78M | -30.93M | -18.58M |
| Operating Cash Flow | -75.57M | -75.57M | -101.73M | -29.78M | -30.67M | -13.13M |
| Investing Cash Flow | -12.70M | -12.70M | -7.25M | 9.63K | -414.16K | -5.48M |
| Financing Cash Flow | 17.37M | 17.37M | 49.43M | 82.98M | 101.35M | 17.99M |
Imugene Technical Analysis
Imugene Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$92.53M | -9.67 | -49.72% | ― | ― | 10.78% | |
47 Neutral | AU$110.99M | -1.09 | -83.09% | ― | ― | 55.94% | |
46 Neutral | AU$145.70M | -7.04 | -81.03% | ― | -20.79% | 73.98% | |
44 Neutral | AU$196.64M | -7.44 | ― | ― | ― | 0.66% | |
44 Neutral | AU$108.11M | -12.79 | -47.98% | ― | 700.00% | 26.88% | |
41 Neutral | AU$97.88M | -5.26 | -42.68% | ― | ― | 63.46% |
Imugene Corporate Events
Imugene Limited has issued 1,736,111 fully paid ordinary shares to CVI Investment Inc. following the conversion of five zero-coupon convertible notes, expanding its share capital without undertaking a separate disclosure to investors. The company confirmed it remains compliant with its financial reporting and continuous disclosure obligations under the Corporations Act and stated there is no excluded information that must be disclosed, signalling routine capital management with no undisclosed material developments for shareholders.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has applied for quotation on the ASX of 1,736,111 new fully paid ordinary shares, with an issue date of 22 December 2025. The additional securities, issued under a previously announced transaction, will increase the company’s quoted share capital, potentially enhancing liquidity in its stock and supporting ongoing corporate and capital management activities.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has notified the market of the issue of 88,233 restricted stock units and 875,675 performance rights awards under its employee incentive scheme, effective 15 December 2025. The unquoted equity issuance, which will not be listed on the ASX, underscores the company’s continued use of equity-based compensation to attract and retain talent, aligning staff incentives with long-term shareholder value and supporting the execution of its strategic and clinical development objectives.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced the cessation of a small tranche of its convertible notes, with 25 IMUAAR convertible securities cancelled by mutual agreement between the company and the noteholder on 18 December 2025. The move marginally simplifies Imugene’s capital structure and slightly reduces its outstanding convertible debt, though the limited size of the cancellation suggests a modest immediate impact on the company’s overall financing position.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has notified the market of the issue of new unquoted securities, comprising 25 new convertible notes and 7,812,500 new warrants, with an issue date of 18 December 2025. These instruments, which are not intended to be quoted on the ASX, form part of previously announced transactions and indicate the company is continuing to utilise structured financing to support its operations and development programs, with potential future dilution implications for existing shareholders depending on conversion and exercise terms.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has reported a change in director Paul Hopper’s interests in the company’s securities following the issue of additional performance rights under its Employee Share Option Plan. Hopper, who holds both direct and indirect share interests, received 124,054 new performance rights at no cost, increasing his total performance rights holding to 260,320, in line with shareholder approval granted at the company’s 13 November 2025 annual general meeting. The transaction, which did not involve any disposal of securities or trading during a closed period, reflects ongoing use of equity-based incentives to align director remuneration with shareholder interests.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced a proposed issue of new securities, comprising up to 25 new convertible notes and 7,812,500 new warrants, with a proposed issue date of 18 December 2025. The capital raising, to be conducted via a placement or similar structure, underscores the company’s ongoing use of equity-linked instruments to fund its operations and growth initiatives, with potential implications for its capital structure and existing shareholders as the additional securities come on line.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced amendments to its existing convertible notes and introduced new convertible notes and warrants valued at A$2.5 million and A$2.75 million, respectively, in collaboration with CVI Investments, Inc. The financial adjustments aim to enhance the company’s cash flow management and provide flexibility, supporting operational stability during the term of the notes. By issuing the new financial instruments under its existing ASX Listing Rule capacity without needing shareholder approval, Imugene strengthens its financial standing and market positioning in the immuno-oncology sector.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced significant progress in its azer-cel program, with strong clinical data and FDA support to advance to the next trial stage. The company expects to reduce operating costs by 50% in the coming year and has formed a strategic collaboration with JW Therapeutics to leverage commercial CAR T infrastructure. The FDA’s positive feedback on Imugene’s dosing regimen and patient population for azer-cel, along with promising clinical results, positions the company to explore additional registrational opportunities, potentially enhancing its market position and offering new hope for blood cancer patients.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced a webinar to discuss positive feedback from the FDA regarding their azer-cel program, highlighting its potential to advance into pivotal studies. This development underscores the program’s clinical and commercial promise, potentially strengthening Imugene’s position in the immuno-oncology market.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has received support from the FDA to advance its azer-cel treatment into a Phase 3 registrational study, targeting patients with relapsed DLBCL after CAR-T therapy. The FDA’s endorsement of Imugene’s dual endpoint strategy and Chemistry Manufacturing Controls readiness signifies a significant opportunity for the company in a high-need setting, potentially enhancing its market position in the immune-oncology sector.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced promising results from its Phase 1b clinical trial of azer-cel, an allogeneic CD19 CAR T therapy for relapsed diffuse large B-cell lymphoma (DLBCL). The trial has achieved an 82% overall response rate, with seven complete and seven partial responses among the patients, many of whom had previously failed multiple lines of therapy. This development highlights the potential of azer-cel in addressing high unmet needs in aggressive blood cancer treatment. The trial is expanding to include CAR T naïve patients with various non-Hodgkin lymphomas, showing meaningful clinical activity and durability of response.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced a strategic collaboration with JW Therapeutics to advance the combination of onCARlytics (CF33-CD19) and Carteyva® for treating solid tumors. The collaboration includes a ‘mark and kill’ strategy for refractory solid tumors, potentially enhancing Imugene’s position in the immuno-oncology field. A webinar will be held to discuss this collaboration, indicating its significance for stakeholders and the company’s future operations.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Ltd and JW Therapeutics have announced a strategic collaboration to evaluate a novel combination therapy using Imugene’s onCARlytics oncolytic virus and JW’s CD19 CAR-T cell therapy, Carteyva®, targeting refractory solid tumors. This collaboration will involve preclinical studies and a Phase 1 trial in China, leveraging a ‘mark and kill’ strategy to make solid tumors targetable by CD19-CAR T cells. The initiative aims to generate impactful data efficiently and explore a breakthrough treatment paradigm for solid tumors, ensuring disciplined capital allocation and strategic flexibility.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced the results of its Annual General Meeting, highlighting a significant shareholder dissent with 30.55% voting against the Remuneration Report, marking a ‘second strike’ under the Corporations Act 2001. Despite this, the Spill Resolution was not passed, with 84.06% voting against it, indicating continued support for the current board and management.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has released a disclaimer regarding its presentation for the Annual General Meeting in November 2025. The company emphasizes that the information provided does not constitute personal investment advice and should not be solely relied upon for making investment decisions. Stakeholders are advised to seek professional investment advice, as the presentation does not account for individual investment objectives or financial situations. Imugene also highlights that the presentation is not an offer to sell or solicit securities in jurisdictions where such actions would be unlawful, including the United States.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced an upcoming webinar to discuss early efficacy results from their azer-cel Phase 1b trial for CAR T naïve lymphomas and their presentation at the 67th American Society of Hematology Annual Meeting. This initiative reflects Imugene’s commitment to advancing cancer treatment and engaging stakeholders, potentially strengthening its position in the immuno-oncology market.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced that its abstract on azer-cel, an allogeneic CD19 CAR T therapy, has been selected for oral presentation at the 67th American Society of Hematology Annual Meeting in Florida. This selection highlights the clinical interest in allogeneic CAR T approaches and provides an opportunity for Imugene to present new insights from their ongoing study on relapsed or refractory large B-cell lymphoma, potentially impacting the company’s industry positioning and stakeholder engagement.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has issued 19,491,635 fully paid ordinary shares to Precision Biosciences, Inc. as part of a milestone achievement under their License Agreement. This issuance reflects Imugene’s progress in its strategic collaboration with Precision Biosciences, potentially enhancing its market position in the immuno-oncology sector. The move signifies Imugene’s commitment to advancing its clinical and commercial milestones, aligning with its vision to become a leader in the rapidly growing global cancer treatment market.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced the issuance of 19,491,635 fully paid ordinary shares to Precision Biosciences, Inc., marking the achievement of a significant milestone under their License Agreement dated August 16, 2023. This development is expected to enhance Imugene’s operational capabilities and strengthen its position in the biotechnology sector by advancing its collaborative efforts with Precision Biosciences.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced a significant milestone in its Phase 1b clinical trial of azer-cel, an allogeneic CD19 CAR T-cell therapy, which has achieved an 81% overall response rate in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial’s success, including rapid and durable responses, positions Imugene favorably in the immuno-oncology sector, with potential implications for expanding treatment options for rare lymphomas. Additionally, the company has raised approximately $25 million through an institutional placement and share purchase plan, and received a $5.9 million R&D tax refund, bolstering its financial position to support ongoing research and development efforts.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced promising early efficacy results from its Phase 1b trial of azer-cel, an allogeneic CD19 CAR T therapy, in CAR T-naïve patients with various B-cell lymphomas. The trial showed an 83% overall response rate and a 50% complete response rate among the six evaluable patients, with enrolment progressing faster than previous cohorts. This progress highlights the substantial clinical demand and potential for expedited clinical paths, particularly in areas of unmet need.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced that its PD1-Vaxx colorectal cancer trial will be featured at the ESMO Congress 2025, highlighting its growing international clinical presence. The Neo-POLEM Phase II trial aims to assess the efficacy of PD1-Vaxx, a novel B-cell vaccine, in treating early-stage MSI-high colorectal cancer, potentially offering an alternative to existing monoclonal antibody therapies. The trial, which began recruitment in May 2025, is a collaborative effort involving multiple sites in the UK and Australia, and seeks to improve treatment outcomes for colorectal cancer patients.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.82 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced the quotation of 2,206 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing projects in cancer immunotherapy. The issuance of these securities reflects Imugene’s commitment to expanding its market presence and advancing its research and development efforts, potentially benefiting stakeholders through increased investment opportunities.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced its 2025 Annual General Meeting, which will address key business matters such as adopting the 2025 Remuneration Report, re-electing directors, and approving equity incentives. The company has made enhancements to its remuneration approach, emphasizing transparency and alignment with performance metrics, and the board intends to forego 50% of equity incentives as a gesture of confidence in challenging capital markets.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.